G-Protein antagonist peptideInhibits G protein activation by GPCRs CAS# 143675-79-0 |
- Cabozantinib (XL184, BMS-907351)
Catalog No.:BCC1264
CAS No.:849217-68-1
- Amuvatinib (MP-470, HPK 56)
Catalog No.:BCC2258
CAS No.:850879-09-3
- TG101209
Catalog No.:BCC2198
CAS No.:936091-14-4
- Ponatinib (AP24534)
Catalog No.:BCC2522
CAS No.:943319-70-8
- Quizartinib (AC220)
Catalog No.:BCC2548
CAS No.:950769-58-1
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 143675-79-0 | SDF | Download SDF |
| PubChem ID | 71308571 | Appearance | Powder |
| Formula | C57H64N12O9S | M.Wt | 1093.27 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | GPAnt-2 | ||
| Solubility | Soluble to 2 mg/ml in DMSO | ||
| Sequence | XQWFWWM (Modifications: X = Glp, Trp-3 = Trp-5 = Trp-6 = D-Trp, Met-7 = C-terminal amide) | ||
| Chemical Name | (2S)-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanediamide | ||
| SMILES | CSCCC(C(=O)N)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(CC6=CNC7=CC=CC=C76)NC(=O)C(CCC(=O)N)NC(=O)C8CCC(=O)N8 | ||
| Standard InChIKey | WSYRBHQWMXTCHQ-SFIKJRKMSA-N | ||
| Standard InChI | InChI=1S/C57H64N12O9S/c1-79-24-23-42(51(59)72)64-55(76)46(26-33-29-60-39-16-8-5-13-36(33)39)69-57(78)48(28-35-31-62-41-18-10-7-15-38(35)41)68-54(75)45(25-32-11-3-2-4-12-32)66-56(77)47(27-34-30-61-40-17-9-6-14-37(34)40)67-53(74)44(19-21-49(58)70)65-52(73)43-20-22-50(71)63-43/h2-18,29-31,42-48,60-62H,19-28H2,1H3,(H2,58,70)(H2,59,72)(H,63,71)(H,64,76)(H,65,73)(H,66,77)(H,67,74)(H,68,75)(H,69,78)/t42-,43-,44-,45-,46+,47+,48+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Substance P-related peptide that inhibits binding of G proteins to their receptors. Competitively and reversibly inhibits M2 muscarinic receptor activation of Gi or Go and inhibits Gs activation by β-adrenoceptors. |
G-Protein antagonist peptide Dilution Calculator
G-Protein antagonist peptide Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Elacridar
Catalog No.:BCC1546
CAS No.:143664-11-3
- Diacetoxy-6-gingerdiol
Catalog No.:BCN3339
CAS No.:143615-75-2
- (2R,3S)-3-Phenylisoserine ethyl ester
Catalog No.:BCC8388
CAS No.:143615-00-3
- 3-(4-Chlorobutyl)indole-5-carbonitrile
Catalog No.:BCC8589
CAS No.:143612-79-7
- Curculigoside B
Catalog No.:BCN7939
CAS No.:143601-09-6
- 5-Hydroxy-2-(4-methoxyphenyl)-8,8-dimethyl-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypyrano[2,3-h]chromen-4-one
Catalog No.:BCC8807
CAS No.:143601-07-4
- Cyclo(Leu-Leu)
Catalog No.:BCN2433
CAS No.:1436-27-7
- A 419259 trihydrochloride
Catalog No.:BCC4308
CAS No.:1435934-25-0
- H-DL-Asp(OMe)-OMe.HCl
Catalog No.:BCC2901
CAS No.:14358-33-9
- Diprenorphine
Catalog No.:BCC5954
CAS No.:14357-78-9
- Virgatic acid
Catalog No.:BCN6744
CAS No.:14356-51-5
- Rocuronium
Catalog No.:BCC1906
CAS No.:143558-00-3
- Fmoc-D-Ile-OPfp
Catalog No.:BCC3507
CAS No.:143688-83-9
- GYKI 53655 hydrochloride
Catalog No.:BCC7407
CAS No.:143692-48-2
- CE3F4
Catalog No.:BCC5605
CAS No.:143703-25-7
- Soyasaponin Bd
Catalog No.:BCN2465
CAS No.:135272-91-2
- Kaempferol 3,4,7-triacetate
Catalog No.:BCN6242
CAS No.:143724-69-0
- Pyrazine-2-carbaldehyde
Catalog No.:BCN2565
CAS No.:5780-66-5
- PACAP 6-38
Catalog No.:BCC7611
CAS No.:143748-18-9
- (RS)-Abscisic acid
Catalog No.:BCN8353
CAS No.:14375-45-2
- 3-O-Coumaroylasiatic acid
Catalog No.:BCN7132
CAS No.:143773-52-8
- SB 200646 hydrochloride
Catalog No.:BCC5751
CAS No.:143797-62-0
- 13-Epimanool
Catalog No.:BCN4862
CAS No.:1438-62-6
- 22-Dehydroclerosterol glucoside
Catalog No.:BCN6243
CAS No.:143815-99-0
Novel antagonist to agonist switch in chimeric G protein-coupled alpha-factor peptide receptors.[Pubmed:7864843]
Biochem Biophys Res Commun. 1995 Feb 15;207(2):559-64.
The alpha-factor analog desTrp1,Ala3 alpha-factor (dTA-alpha-factor) acts as an antagonist for both the S. cerevisiae alpha-factor receptor (c-alpha-FR) and the S. kluyveri alpha-factor receptor (k-alpha FR). Chimeric alpha-factor receptors in which a portion (residues 250-303) of the seven hydrophobic segments were derived from the k-alpha FR and the rest from c-alpha FR conferred potent activation of cellular responses by dTA-alpha-factor including induction of FUS1 expression without significantly affecting binding. Chimeric receptors with all hydrophobic segments derived from one receptor did not express sensitivity. We propose that dTA-alpha-factor represents an antagonist that that has an activation energy barrier to activating c-alpha FR and k-alpha FR but which retains a latent potential to act as an agonist.
CART peptide stimulation of G protein-mediated signaling in differentiated PC12 cells: identification of PACAP 6-38 as a CART receptor antagonist.[Pubmed:21855138]
Neuropeptides. 2011 Oct;45(5):351-8.
CART peptides are peptide neurotransmitters and hormones that are involved in many different physiological responses. While much is known about the peptides regarding their structure, processing and gene regulation, less is known about their postsynaptic actions and receptors. Using (125)I-CART 61-102 as a ligand and unlabeled CART 61-102 or CART 55-102 as displacers, high-affinity specific binding was detected in PC12 cells. Differentiation of the PC12 cells increased specific binding several-fold. The increase in specific binding found after differentiation was inhibited by actinomycin D and cycloheximide, suggesting that the increase in specific binding was dependent on RNA and protein synthesis. CART 1-27, a peptide that has never been shown to elicit responses, did not displace (125)I-CART 61-102 binding, nor did more than 20 other peptides that were examined. Surprisingly, however, PACAP 1-38 and PACAP 6-38 were found to be low-affinity inhibitors of CART binding. CART treatment increased binding of (35)S-GTPgamma-S to PC12 cell membranes. Moreover, CART treatment of intact PC12 cells elicited robust increases in phospho-ERK in a manner that was increased with differentiation, blocked by pertussis toxin and antagonized by PACAP 6-38. These findings extend previous research and suggest that the CART binding site in PC12 cells reflects a G protein-coupled receptor linked with Gi/o, and also demonstrate that PACAP 6-38 may be useful as a CART receptor antagonist.
G protein antagonists. A novel hydrophobic peptide competes with receptor for G protein binding.[Pubmed:1379592]
J Biol Chem. 1992 Aug 15;267(23):16237-43.
A substance P (SP) analog, [D-Pro4,D-Trp7,9,10] SP4-11, is known to inhibit the actions of various structurally unrelated messenger molecules as well as SP. Our studies on the effects of this peptide on the regulation of purified G proteins by receptor showed that at least some of the biological effects of the peptide can be explained by the ability of the peptide to block the activation of G proteins by receptors. Here we report that a novel truncated SP-related peptide, pGlu-Gln-D-Trp-Phe-D-Trp-D-Trp-Met-NH2, inhibited the activation of G(i) or G(o) by M2 muscarinic cholinergic receptor (M2 mAChR) or of Gs by beta-adrenergic receptor in the reconstituted phospholipid vesicles, assayed by receptor-promoted GTP hydrolysis. The inhibition by the peptide was apparently reversible and competitive with respect to receptor binding to G proteins; the inhibition could be overcome by increasing the concentration of receptor in the vesicles and was not altered by changes in the concentration of G protein. The competing effects of the peptide were used to analyze the effect of agonist on receptor-G protein interaction. The concentration change of muscarinic agonist did not alter the inhibitory effects of the peptide on M2 mAChR-promoted GTPase by G(o), which is consistent with the idea that agonist increases the regulatory efficiency of the receptor but does not alter its affinity for G proteins. This new group of compounds (G protein antagonists) is a promising tool to study receptor-G protein interaction quantitatively.
